Skip to main content
. 2021 Jun 7;113(12):1733–1743. doi: 10.1093/jnci/djab108

Figure 3.

Figure 3.

Clinical activity in assay-defined biomarker-evaluable populations (BEPs). Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) in BEPs by programmed death-ligand 1 (PD-L1)–positive or –negative status for SP142 tumor-infiltrating immune cells (IC) 1% (A), SP263 IC 1% (B), 22C3 IC 1% (C), and 22C3 combined positive score (CPS) 1 (D). A = atezolizumab; nP = nab-paclitaxel; P = placebo.